Sec Form 3 Filing - TSSP Sub-Fund HoldCo LLC @ Caris Life Sciences, Inc. - 2025-06-17

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person TSSP Sub-Fund HoldCo LLC 2. Issuer Name and Ticker or Trading Symbol Caris Life Sciences, Inc. [ CAI] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O SIXTH STREET PARTNERS, LLC, 2100 MCKINNEY AVENUE, SUITE 1500 3. Date of Earliest Transaction (MM/DD/YY) 06/17/2025 (Street) DALLAS, TX75201 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 6,884,058 I Held by Barnett Equity Holdings, LLC ( 5 ) ( 7 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 15,527,951 I Held by TOP III Barnett Investments, LLC ( 5 ) ( 7 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 13,975,155 I Held by TAO Barnett Investments LLC ( 5 ) ( 7 ) Series C Preferred Stock ( 1 ) ( 1 ) ( 1 ) Common Stock 1,915,114 I Held by Sixth Street Specialty Lending, Inc. ( 6 ) ( 7 ) Series D Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 1,240,740 I Held by Sixth Street Specialty Lending, Inc. ( 6 ) ( 7 ) Series D Preferred Stock ( 2 ) ( 2 ) ( 2 ) Common Stock 23,574,073 I Held by Barnett Equity Holdings II, LLC ( 5 ) ( 7 ) 2018 Warrants ( 3 ) ( 3 ) 09/20/2025 Common Stock ( 3 ) 13,009,892 I Held by Barnett Equity Holdings, LLC ( 5 ) ( 7 ) 2018 Warrants ( 3 ) ( 3 ) 09/20/2025 Common Stock ( 3 ) 684,731 I Held by Sixth Street Specialty Lending, Inc. ( 6 ) ( 7 ) 2020 Warrants ( 4 ) ( 4 ) 04/02/2027 Common Stock ( 4 ) 10,829,823 I Held by Barnett Equity Holdings, LLC ( 5 ) ( 7 ) 2020 Warrants ( 4 ) ( 4 ) 04/02/2027 Common Stock ( 4 ) 569,991 I Held by Sixth Street Specialty Lending, Inc. ( 6 ) ( 7 )

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other TSSP Sub-Fund HoldCo LLC C/O SIXTH STREET PARTNERS, LLC 2100 MCKINNEY AVENUE, SUITE 1500 DALLAS, TX75201 X Waxman Alan 1 LETTERMAN DRIVE BUILDING B, SUITE B6-100 SAN FRANCISCO, CA94129 X Signatures TSSP Sub-Fund Holdco, LLC, By: /s/ Joshua Peck, Vice President 06/17/2025 Signature of Reporting Person Date Alan Waxman By: /s/ Joshua Peck, on behalf of Alan Waxman 06/17/2025 Signature of Reporting Person Date

Explanation of Responses :

( 1 )Each share of Series C Preferred Stock of Caris Life Sciences, Inc. (the "Issuer") is convertible at the option of the holder into 0.25 shares of common stock $.001 par value of the Issuer (the "Common Stock") and will automatically convert into Common Stock immediately prior to and in connection with the closing of the Issuer's initial public offering (the "IPO"), subject to adjustment pursuant to the terms of the Issuer's amended and restated certificate of formation (the "Charter") in connection with the IPO. The Series C Preferred Stock is currently convertible and has no expiration date. ( 2 )Each share of Series D Preferred Stock of the Issuer is convertible at the option of the holder into 0.25 shares of Common Stock of the Issuer and will automatically convert into Common Stock immediately prior to and in connection with the closing of the Issuer's IPO, subject to adjustment pursuant to the terms of the Charter in connection with the IPO. The Series D Preferred Stock is currently convertible and has no expiration date. ( 3 )The 2018 warrants are currently exercisable at the option of the holder into shares of Series C Preferred Stock of the Issuer at an exercise price of $1.61 per share and into Common Stock at an exercise price of $6.44 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2018 warrants will be exercised on a cashless basis into shares of Series C Preferred Stock which will then automatically convert into Common Stock, subject to adjustment pursuant to the terms of the Charter in connection with the IPO. ( 4 )The 2020 warrants are currently exercisable into Series C preferred stock at a price of $1.93 per share and into Common Stock at a price of $7.73 per share. Immediately prior to and in connection with the closing of the Issuer's IPO the 2020 warrants will be exercised on a cashless basis into shares of Series C Preferred Stock which will then automatically convert into Common Stock, subject to adjustment pursuant to the terms of the Charter in connection with the IPO. ( 5 )TSSP Sub-Fund Holdco, LLC, a Delaware limited liability company ("Sub-Fund HoldCo"), is the sole member of each of TAO SPV GP, LLC, a Delaware limited liability company ("TAO SPV"), and Empire SPV GP, LLC, a Delaware limited liability company ("Empire SPV"). TAO SPV is the managing member of each of (i) Barnett Equity Holdings, LLC; (ii) Barnett Equity Holdings II LLC; and (iii) TAO Barnett Investments LLC. Empire SPV is the managing member of TOP III Barnett Investments, LLC. ( 6 )TSSP Holdco Management, LLC, a Delaware limited liability company ("Holdco Management"), manages Sixth Street Specialty Lending Advisers Holdings, LLC, a Delaware limited liability company ("Adviser Holdings"). The business and affairs of Sixth Street Specialty Lending Advisers, LLC, a Delaware limited liability company ("Adviser"), are managed by Adviser Holdings, the sole member of Adviser. Sixth Street Specialty Lending, Inc. is managed by Adviser. ( 7 )Sub-Fund HoldCo is managed by its sole member, whose managing member is Alan Waxman ("Mr. Waxman"). Holdco Management is managed by a board of directors, which is currently comprised of Mr. Waxman. Mr. Waxman is the CEO of Holdco Management. Each Reporting Person disclaims beneficial ownership over the reported securities herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of its or his pecuniary interest therein.

Remarks: Exhibit 24 - Authorization and Designation Letter, dated December 31, 2024, by Alan Waxman

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.